Download Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Light Targeted Therapies Market: By Type, By Indication, and Region Forecast 2020-2031
Light Targeted Therapies Market: By Type, By Indication, and Region Forecast 2020-2031
Light Targeted Therapies Market size was valued at US$ 937.7 million in 2024 and is projected to reach US$ 1,328.3 million in 2031, growing at a 5.1% CAGR from 2025 to 2031. Light-targeted therapies, a rapidly evolving field in medicine, utilize light to activate therapeutic agents or directly target diseased cells. The market is experiencing a surge in interest due to its minimally invasive and potentially precise approach to treating various medical conditions. The growing global aging population creates a rising need for treatments for age-related conditions like macular degeneration and arthritis. Light-targeted therapies are being explored for potential applications in treating these conditions.
The market is driven by a confluence of factors that prioritize patient outcomes, technological advancements, and a growing demand for innovative treatment options. Moreover, advancements in light source technology, including lasers and LEDs, are enabling more precise and powerful light delivery for targeted therapies. These advancements allow for deeper tissue penetration and improved treatment efficacy. The integration of image-guided technologies like ultrasound or MRI with light-targeted therapies ensures accurate targeting of treatment areas, further enhancing treatment effectiveness and safety.
Furthermore, the development of light-sensitive nanoparticles holds immense potential for light-targeted therapies. These nanoparticles can be designed to accumulate in specific tissues and be activated by light to deliver localized drug delivery or induce cell death. However, developing and conducting clinical trials for light-targeted therapies can be expensive. These high development costs can translate to high treatment costs for patients, potentially limiting accessibility.
Study Period
2025-2031Base Year
2024CAGR
5.1%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
Light-targeted therapies often offer minimally invasive procedures compared to traditional treatments like surgery. This attributes to quicker recovery times, reduced post-operative pain, and fewer potential complications for patients. The light-targeted therapies can potentially target specific diseased cells or tissues while leaving healthy tissue unharmed. This improved specificity can lead to fewer side effects and more favourable outcomes for patients.
In addition, some light-targeted therapies offer a potential advantage over traditional therapies by reducing the risk of developing resistance. This is particularly beneficial for treating chronic conditions. Moreover, the increasing prevalence of chronic diseases like cancer, diabetes, and neurodegenerative diseases is driving the demand for novel and effective treatment options. Light-targeted therapies offer a promising approach for treating these conditions. Also, the limitations associated with traditional treatments, such as surgery, chemotherapy, and radiation therapy, are propelling the search for alternative approaches. Light-targeted therapies offer a potential solution with their minimally invasive nature and improved specificity.
North America currently holds the dominant position in the light-targeted therapies market. The region boasts a well-developed research infrastructure with leading academic institutions and pharmaceutical companies actively researching and developing novel light-targeted therapies. In addition, government agencies and private investors provide significant funding for research and development of innovative medical technologies, including light-targeted therapies. Also, healthcare providers in North America are generally early adopters of new and promising medical technologies. This early adoption fosters rapid growth in the light-targeted therapies market.
Moreover, a well-established and robust regulatory framework ensures patient safety and encourages ethical development of light-targeted therapies. The Asia Pacific region is experiencing the fastest growth in the light-targeted therapies market, driven by factors such as growing aging population, increasing healthcare expenditure, and growing focus on innovation.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 937.7 million |
|
Market Size in 2031 |
US$ 1,328.3 million |
|
Market CAGR |
5.1% |
|
By Type |
|
|
By Indication |
|
|
By Region |
|
Download Free Sample Report
Light Targeted Therapies Market size was valued at US$ 937.7 million in 2024 and is projected to reach US$ 1,328.3 million in 2031 growing at a 5.1% CAGR from 2025 to 2031.
The Asia Pacific is the fastest-growing region
The leading players in the Light Targeted Therapies Market are Rakuten Medical, Novartis, Galderma, ADVANZ PHARMA, Biofrontera, Sun Pharma, Modulight Corporation, biolitec Pharma, Luzitin, Nanospectra Biosciences, Photoatomic, Steba biotech, and Theralase.
| 1. Executive Summary |
| 2. Global Light-Targeted Therapies Market Introduction |
| 2.1. Global Light Targeted Therapies Market Taxonomy |
| 2.2. Global Light Targeted Therapies Market Definitions |
| 2.2.1. By Type |
| 2.2.2. By Indication |
| 2.2.3. By Region |
| 3. Global Light Targeted Therapies Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. R&D Trends |
| 3.5. Pipeline Drugs |
| 3.6. List of Developers |
| 3.7. Clinical Developmental Status (End Points, Dose Regimen, and Others) |
| 3.8. Disease Landscape |
| 3.9. Global Light Targeted Therapies Market Dynamic Factors - Impact Analysis |
| 3.10. Three Forecast Scenarios - Pessimistic, Conservative and Opportunistic |
| 3.11. Mapping Market Players Activities |
| 3.12. Recent Key Developments |
| 3.13. Financial Status of the Market Players |
| 3.14. Recent Acquisitions, Collaborations and Mergers |
| 4. Global Light Targeted Therapies Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Light Targeted Therapies Market Forecast, By Type, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 5.1. Photodynamic Therapy |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Photoimmunotherapy |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Photothermal Therapy |
| 5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Light Targeted Therapies Market Forecast, By Indication, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 6.1. Head and Neck Cancer |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Actinic Keratosis |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Macular Degeneration |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Polypoidal Choroidal Vasculopathy |
| 6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Cervical Intraepithelial Neoplasia |
| 6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Bladder Cancer |
| 6.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Esophageal Cancer |
| 6.7.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 6.8. Gastric Cancer |
| 6.8.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.8.3. Market Opportunity Analysis |
| 6.9. Lung Cancer |
| 6.9.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 6.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.9.3. Market Opportunity Analysis |
| 6.10. Port-Wine Stain |
| 6.10.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 6.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.10.3. Market Opportunity Analysis |
| 6.11. Others |
| 6.11.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 6.11.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.11.3. Market Opportunity Analysis |
| 7. Global Light Targeted Therapies Market Forecast, By Region, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Light Targeted Therapies Market - Opportunity Analysis Index, By Type, by Indication, and Region, 2025 - 2031 |
| 8. North America Light Targeted Therapies Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 8.1. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
| 8.1.1. Photodynamic Therapy |
| 8.1.2. Photoimmunotherapy |
| 8.1.3. Photothermal Therapy |
| 8.2. Pressure Range Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
| 8.2.1. Head and Neck Cancer |
| 8.2.2. Actinic Keratosis |
| 8.2.3. Macular Degeneration |
| 8.2.4. Polypoidal Choroidal Vasculopathy |
| 8.2.5. Cervical Intraepithelial Neoplasia |
| 8.2.6. Bladder Cancer |
| 8.2.7. Barretts Esophagus |
| 8.2.8. Gastric Cancer |
| 8.2.9. Lung Cancer |
| 8.2.10. Port-Wine Stain |
| 8.2.11. Others |
| 8.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. U.S. |
| 8.3.2. Canada |
| 8.4. North America Light Targeted Therapies Market - Opportunity Analysis Index, By Type, Indication, and Country, 2025 - 2031 |
| 8.5. North America Light Targeted Therapies Market Dynamics Trends |
| 9. Europe Light Targeted Therapies Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 9.1. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
| 9.1.1. Photodynamic Therapy |
| 9.1.2. Photoimmunotherapy |
| 9.1.3. Photothermal Therapy |
| 9.2. Pressure Range Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. Head and Neck Cancer |
| 9.2.2. Actinic Keratosis |
| 9.2.3. Macular Degeneration |
| 9.2.4. Polypoidal Choroidal Vasculopathy |
| 9.2.5. Cervical Intraepithelial Neoplasia |
| 9.2.6. Bladder Cancer |
| 9.2.7. Esophageal Cancer |
| 9.2.8. Gastric Cancer |
| 9.2.9. Lung Cancer |
| 9.2.10. Port-Wine Stain |
| 9.2.11. Others |
| 9.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Germany |
| 9.3.2. UK |
| 9.3.3. France |
| 9.3.4. Italy |
| 9.3.5. Spain |
| 9.3.6. Rest of Europe |
| 9.4. Europe Light Targeted Therapies Market - Opportunity Analysis Index, By Type, Indication, and Country, 2025 - 2031 |
| 9.5. Europe Light Targeted Therapies Market Dynamics Trends |
| 10. Asia-Pacific Light Targeted Therapies Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 10.1. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
| 10.1.1. Photodynamic Therapy |
| 10.1.2. Photoimmunotherapy |
| 10.1.3. Photothermal Therapy |
| 10.2. Pressure Range Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Head and Neck Cancer |
| 10.2.2. Actinic Keratosis |
| 10.2.3. Macular Degeneration |
| 10.2.4. Polypoidal Choroidal Vasculopathy |
| 10.2.5. Cervical Intraepithelial Neoplasia |
| 10.2.6. Bladder Cancer |
| 10.2.7. Esophageal Cancer |
| 10.2.8. Gastric Cancer |
| 10.2.9. Lung Cancer |
| 10.2.10. Port-Wine Stain |
| 10.2.11. Others |
| 10.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Japan |
| 10.3.2. China |
| 10.3.3. India |
| 10.3.4. ASEAN |
| 10.3.5. Rest of Asia-Pacific |
| 10.4. Asia-Pacific Light Targeted Therapies Market - Opportunity Analysis Index, By Type, Indication, and Country, 2025 - 2031 |
| 10.5. Asia-Pacific Light Targeted Therapies Market Dynamics Trends |
| 11. Latin America Light Targeted Therapies Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 11.1. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.1.1. Photodynamic Therapy |
| 11.1.2. Photoimmunotherapy |
| 11.1.3. Photothermal Therapy |
| 11.2. Pressure Range Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Head and Neck Cancer |
| 11.2.2. Actinic Keratosis |
| 11.2.3. Macular Degeneration |
| 11.2.4. Polypoidal Choroidal Vasculopathy |
| 11.2.5. Cervical Intraepithelial Neoplasia |
| 11.2.6. Bladder Cancer |
| 11.2.7. Esophageal Cancer |
| 11.2.8. Gastric Cancer |
| 11.2.9. Lung Cancer |
| 11.2.10. Port-Wine Stain |
| 11.2.11. Others |
| 11.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Argentina |
| 11.3.3. Rest of Latin America |
| 11.4. Latin America Light Targeted Therapies Market - Opportunity Analysis Index, By Type, Indication, and Country, 2025 - 2031 |
| 11.5. Latin America Light Targeted Therapies Market Dynamics Trends |
| 12. Middle East and Africa Light Targeted Therapies Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, US$ Million) |
| 12.1. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.1.1. Photodynamic Therapy |
| 12.1.2. Photoimmunotherapy |
| 12.1.3. Photothermal Therapy |
| 12.2. Pressure Range Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Head and Neck Cancer |
| 12.2.2. Actinic Keratosis |
| 12.2.3. Macular Degeneration |
| 12.2.4. Polypoidal Choroidal Vasculopathy |
| 12.2.5. Cervical Intraepithelial Neoplasia |
| 12.2.6. Bladder Cancer |
| 12.2.7. Esophageal Cancer |
| 12.2.8. Gastric Cancer |
| 12.2.9. Lung Cancer |
| 12.2.10. Port-Wine Stain |
| 12.2.11. Others |
| 12.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Saudi Arabia |
| 12.3.2. GCC Countries |
| 12.3.3. South Africa |
| 12.3.4. Rest of MEA |
| 12.4. MEA Light Targeted Therapies Market - Opportunity Analysis Index, By Type, Indication, and Country, 2025 - 2031 |
| 12.5. MEA Light Targeted Therapies Market Dynamics Trends |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, Type Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. Rakuten Medical |
| 13.2.2. Novartis |
| 13.2.3. Galderma |
| 13.2.4. ADVANZ PHARMA |
| 13.2.5. Biofrontera |
| 13.2.6. Sun Pharma |
| 13.2.7. Modulight Corporation |
| 13.2.8. biolitec Pharma |
| 13.2.9. Luzitin |
| 13.2.10. Nanospectra Biosciences |
| 13.2.11. Photoatomic |
| 13.2.12. Steba biotech |
| 13.2.13. Theralase |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.